MCID: CRV031
MIFTS: 53

Cervical Adenocarcinoma malady

Categories: Reproductive diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Cervical Adenocarcinoma

Aliases & Descriptions for Cervical Adenocarcinoma:

Name: Cervical Adenocarcinoma 12 56 52 14 69
Adenocarcinoma of the Uterine Cervix 12
Adenocarcinoma of Cervix Uteri 56
Adenocarcinoma Cervix Uteri 12
Adenocarcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3702
NCIt 47 C4029
Orphanet 56 ORPHA213772
ICD10 via Orphanet 34 C53.0 C53.1 C53.8
UMLS 69 C0279672

Summaries for Cervical Adenocarcinoma

Disease Ontology : 12 A cervix carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Cervical Adenocarcinoma, also known as adenocarcinoma of the uterine cervix, is related to sagittal sinus thrombosis and nasopharyngeal carcinoma. An important gene associated with Cervical Adenocarcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Glioma and Development HGF signaling pathway. The drugs Gardasil and Menthol have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and testes, and related phenotypes are cellular and digestive/alimentary

Related Diseases for Cervical Adenocarcinoma

Diseases in the Cervical Adenocarcinoma family:

Early Invasive Cervical Adenocarcinoma

Diseases related to Cervical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 228)
id Related Disease Score Top Affiliating Genes
1 sagittal sinus thrombosis 29.6 CDX2 KRT20 KRT7
2 nasopharyngeal carcinoma 29.5 CDKN1A CDKN2A TP53
3 early invasive cervical adenocarcinoma 12.0
4 glassy cell carcinoma of the cervix 11.1
5 cervicitis 10.7
6 adenocarcinoma 10.7
7 clear cell adenofibroma 10.3 CDKN2A TP53
8 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
9 radiculopathy 10.3 KRT20 KRT7
10 adult myxoid chondrosarcoma 10.3 KRT20 KRT7
11 suppurative lymphadenitis 10.3 CDKN2A KRT7
12 pericardium leiomyoma 10.3 CDKN2A TP53
13 bronchus mucoepidermoid carcinoma 10.3 KRT20 KRT7
14 bladder clear cell adenocarcinoma 10.3 ESR1 TP53
15 steroid-induced glaucoma - borderline 10.3 KRT20 KRT7
16 non specific chronic endometritis 10.3 KRT20 KRT7
17 adenocarcinoma in situ 10.3
18 neuroendocrine tumor 10.3 CDX2 KRT20 PTGS2
19 bile duct clear cell adenocarcinoma 10.3 PTGS2 TP53
20 urethral verrucous carcinoma 10.3 CDKN2A PTGS2 TP53
21 endometrial squamous cell carcinoma 10.3 CDKN2A RASSF1 TP53
22 spinal cord oligodendroglioma 10.3 CDKN2A KRT20 TP53
23 placental site trophoblastic tumor 10.2 CDKN2A KRT20 TP53
24 aicardi-goutieres syndrome 10.2 CDKN2A CDX2 TP53
25 peritoneal benign neoplasm 10.2 CDX2 KRT20 KRT7
26 dystonia 10.2 CDX2 KRT20 KRT7
27 anal canal paget's disease 10.2 CDX2 KRT20 KRT7
28 giant cell tumor 10.2 CDX2 KRT20 TP53
29 tabes dorsalis 10.2 CDX2 KRT20 TP53
30 spondylarthropathy 10.2 CDKN2A TP53
31 mucosal melanoma 10.2 CDX2 KRT20 KRT7
32 anemia of prematurity 10.2 CDX2 KRT20 KRT7
33 tumor of exocrine pancreas 10.2 CDKN2A ESR1 KRT20
34 ovarian mucinous neoplasm 10.2 CDX2 PTGS2 TP53
35 hunter macpherson syndrome 10.2 CDX2 KRT20 KRT7
36 anal carcinoma in situ 10.2 CDKN2A KRT7 TP53
37 churg-strauss syndrome 10.2 CDX2 KRT20 KRT7
38 hyperornithinemia-hyperammonemia-homocitrullinemia syndrome 10.2 CDX2 PTGS2 TP53
39 plasmodium ovale malaria 10.2 CDKN2A KRT7 TP53
40 acute retinal necrosis syndrome 10.2 CDX2 KRT20 KRT7
41 acute mountain sickness 10.2 CDKN1A TP53
42 ariboflavinosis 10.2 CDX2 KRT20 KRT7
43 malignant mediastinal neurogenic neoplasm 10.2 CEACAM5 TP53
44 nodular cutaneous amyloidosis 10.2 CDKN2A KRT7 TP53
45 childhood-onset cerebral x-linked adrenoleukodystrophy 10.2 CDKN2A RASSF1 TP53
46 cervical verrucous carcinoma 10.2 CDKN1A CDKN2A TP53
47 clitoris cancer 10.2 CDX2 KRT20
48 skeletal tuberculosis 10.2 CDKN2A ERBB2
49 rhinitis 10.2 ESR1 KRT20 TP53
50 deep angioma 10.2 CEACAM5 KRT7

Graphical network of the top 20 diseases related to Cervical Adenocarcinoma:



Diseases related to Cervical Adenocarcinoma

Symptoms & Phenotypes for Cervical Adenocarcinoma

MGI Mouse Phenotypes related to Cervical Adenocarcinoma:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.28 CASP3 CDKN1A CDKN2A CDX2 ERBB2 ESR1
2 digestive/alimentary MP:0005381 10.22 CASP3 CDKN1A CDKN2A CDX2 ERBB2 ESR1
3 homeostasis/metabolism MP:0005376 10.22 ERBB2 ESR1 KRT7 PTGS2 RASSF1 TP53
4 cardiovascular system MP:0005385 10.2 CASP3 CDKN1A CDKN2A CDX2 ERBB2 ESR1
5 endocrine/exocrine gland MP:0005379 10.15 CASP3 CDKN1A CDKN2A CDX2 ERBB2 ESR1
6 integument MP:0010771 10.06 CDKN1A CDKN2A ERBB2 ESR1 LAMC2 PTGS2
7 embryo MP:0005380 10.05 CDKN1A CDKN2A CDX2 ERBB2 ESR1 PTGS2
8 neoplasm MP:0002006 9.92 CDKN1A CDKN2A CDX2 ERBB2 ESR1 PTGS2
9 limbs/digits/tail MP:0005371 9.91 CDKN1A CDX2 ERBB2 ESR1 LAMC2 TP53
10 muscle MP:0005369 9.91 CASP3 CDKN1A CDKN2A ERBB2 ESR1 PTGS2
11 liver/biliary system MP:0005370 9.88 CDKN1A CDKN2A ESR1 PTGS2 RASSF1 TP53
12 renal/urinary system MP:0005367 9.8 CASP3 CDKN1A ESR1 KRT7 LAMC2 PTGS2
13 reproductive system MP:0005389 9.76 CASP3 CDKN1A CDKN2A CDX2 ERBB2 ESR1
14 respiratory system MP:0005388 9.56 CASP3 CDKN1A CDKN2A ERBB2 ESR1 LAMC2
15 skeleton MP:0005390 9.28 CASP3 CDKN1A CDKN2A CDX2 ERBB2 ESR1

Drugs & Therapeutics for Cervical Adenocarcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Approved June 2006

Drugs for Cervical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 413)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
3
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
4
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
5
Levoleucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
6
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
7
Nicotine Approved Phase 4 54-11-5 942 89594
8
Iron Approved Phase 4 7439-89-6 23925
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
11
Camptothecin Experimental Phase 4,Phase 2,Phase 1 7689-03-4
12 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
13 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
14 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
15 Antidotes Phase 4,Phase 3,Phase 2,Phase 1
16 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
19 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
22 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1
23 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
25 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
26 Epoetin alfa Phase 4,Phase 3 113427-24-0
27 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
28 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
29 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
30 Central Nervous System Stimulants Phase 4,Phase 3
31 Cholinergic Agents Phase 4
32 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Nicotinic Agonists Phase 4
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
35 Ferric Compounds Phase 4
36 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
37 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
38
Epirubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 56420-45-2 41867
39
Capecitabine Approved, Investigational Phase 2, Phase 3, Phase 1 154361-50-9 60953
40
Cetuximab Approved Phase 2, Phase 3, Phase 1 205923-56-4 56842117 2333
41
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
42
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
43
Pancrelipase Approved Phase 3,Phase 1,Phase 2 53608-75-6
44
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
45
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
46
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
47
Succinylcholine Approved Phase 3,Phase 1,Phase 2 306-40-1 5314
48
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
49
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
50
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903

Interventional clinical trials:

(show top 50) (show all 748)
id Name Status NCT ID Phase
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4
3 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
5 Iron Replacement in Oesophagogastric Neoplasia Recruiting NCT01927328 Phase 4
6 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4
7 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
8 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4
9 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Not yet recruiting NCT03180034 Phase 4
10 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3
11 Combination Chemotherapy in Treating Patients With Esophageal Cancer Unknown status NCT00041262 Phase 3
12 Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett Esophagus Unknown status NCT00987857 Phase 3
13 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3
14 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3
15 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3
16 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3
17 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3
18 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3
19 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3
20 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Completed NCT00262821 Phase 3
21 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3
22 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3
23 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
24 Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants Completed NCT00128661 Phase 3
25 Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis Completed NCT00052962 Phase 3
26 Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Completed NCT01640782 Phase 3
27 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed NCT00917384 Phase 3
28 Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer Completed NCT00140075 Phase 3
29 Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. Completed NCT00056459 Phase 3
30 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3
31 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
32 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
33 A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer Completed NCT01249352 Phase 2, Phase 3
34 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
35 Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00026338 Phase 3
36 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3
37 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
38 Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer Completed NCT00062426 Phase 3
39 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3
40 Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer Completed NCT00020787 Phase 3
41 Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00003118 Phase 3
42 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00002631 Phase 3
43 Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer Completed NCT00861094 Phase 2, Phase 3
44 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3
45 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Recruiting NCT01414608 Phase 3
46 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3
47 Laparoscopic Approach to Cervical Cancer Recruiting NCT00614211 Phase 3
48 Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation Recruiting NCT02741856 Phase 2, Phase 3
49 Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction Recruiting NCT01962246 Phase 2, Phase 3
50 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3

Search NIH Clinical Center for Cervical Adenocarcinoma

Genetic Tests for Cervical Adenocarcinoma

Anatomical Context for Cervical Adenocarcinoma

MalaCards organs/tissues related to Cervical Adenocarcinoma:

39
Cervix, Lymph Node, Testes, Ovary, Colon, Uterus, Breast

Publications for Cervical Adenocarcinoma

Articles related to Cervical Adenocarcinoma:

(show top 50) (show all 310)
id Title Authors Year
1
Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27566027 )
2016
2
Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and metaanalysis. ( 27133009 )
2016
3
Uterine cervical adenocarcinoma metastasizing concurrently to eutopic and ectopic ovaries: A case report. ( 27005982 )
2016
4
Comment on: Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27793441 )
2016
5
Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study. ( 27227411 )
2016
6
Cytomorphology of Gastric-Type Cervical Adenocarcinoma on a ThinPrep Pap Test: Report of a p16-Positive Tumor Case. ( 27165398 )
2016
7
Analysis of the expression and localization of tight junction transmembrane proteins, claudin-1, -4, -7, occludin and JAM-A, in human cervical adenocarcinoma. ( 26847087 )
2016
8
Correlation between EGFR Expression and Radiosensitivity in Cervical Adenocarcinoma Cases. ( 27268625 )
2016
9
Human Leukocyte Antigen-DR Expression is Significantly Related to an Increased Disease-Free and Disease-Specific Survival in Patients With Cervical Adenocarcinoma. ( 27654088 )
2016
10
Cervical adenocarcinoma with stromal micropapillary pattern. ( 26608235 )
2016
11
Prevalence of HPV genotypes in cervical adenocarcinoma: a study in Greek women. ( 27569088 )
2016
12
Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis. ( 27977543 )
2016
13
Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors. ( 27677664 )
2016
14
Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors. ( 27639249 )
2016
15
Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma. ( 27102248 )
2016
16
Case images: Cervical adenocarcinoma presenting with a terrible combination: a giant cardiac mass, cardiac tamponade and pulmonary embolism. ( 28045425 )
2016
17
Biology and treatment of cervical adenocarcinoma. ( 27198186 )
2016
18
The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China. ( 27554015 )
2016
19
Cervical Adenocarcinoma: Are We Screening and Treating Patients Appropriately? ( 27529155 )
2016
20
Clinicopathologic Factors of Cervical Adenocarcinoma Stages IB to IIB. ( 26495760 )
2015
21
The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ. ( 25956340 )
2015
22
FoxP3(+) and IL-17(+) cells are correlated with improved prognosis in cervical adenocarcinoma. ( 25795131 )
2015
23
Primary debulking surgery for metastatic cervical adenocarcinoma: A case report. ( 26793767 )
2015
24
The problem of late ovarian metastases from primary cervical adenocarcinoma. ( 26425714 )
2015
25
The complex relationship between human papillomavirus and cervical adenocarcinoma. ( 26334557 )
2015
26
Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard? ( 25769659 )
2015
27
Patterns of Invasion of Cervical Adenocarcinoma as Predicators of Outcome. ( 26452210 )
2015
28
Combination of external beam radiotherapy and Californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma. ( 26271794 )
2015
29
LTPB2 acts as a prognostic factor and promotes progression of cervical adenocarcinoma. ( 26279753 )
2015
30
Macrophage immigration inhibitory factor promotes cell proliferation and inhibits apoptosis of cervical adenocarcinoma. ( 25716200 )
2015
31
High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma. ( 25871737 )
2015
32
Increased expression of iASPP correlates with poor prognosis in FIGO IA2-IIA cervical adenocarcinoma following a curative resection. ( 26046000 )
2015
33
Robot-Assisted Laparoscopic Partial Colpectomy and Intracorporeal Ileal Conduit Urinary Diversion (Bricker) for Cervical Adenocarcinoma Recurrence. ( 26634161 )
2015
34
Laparoscopic hysterectomy with morcellation for a suspected uterine fibroid resulting in dissemination of cervical adenocarcinoma: A case report. ( 26076147 )
2015
35
Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3. ( 25719555 )
2015
36
Prognostic factors affecting cervical adenocarcinoma: 10A years experience in a single institution. ( 25851496 )
2015
37
Widespread recurrence 7 years after radical abdominal trachelectomy for early cervical adenocarcinoma. ( 25918655 )
2015
38
Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery. ( 26028100 )
2015
39
Methanolic Extracts from Brown Seaweeds Dictyota cilliolata and Dictyota menstrualis Induce Apoptosis in Human Cervical Adenocarcinoma HeLa Cells. ( 25871374 )
2015
40
Repeated episodes of spontaneous regression/progression of cervical adenocarcinoma after adjuvant chemoradiation therapy: a case report. ( 25985999 )
2015
41
CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway. ( 26404133 )
2015
42
Detection of human papillomavirus in chronic cervicitis, cervical adenocarcinoma, intraepithelial neoplasia and squamus cell carcinoma. ( 25147721 )
2014
43
Protection against squamous cell carcinoma and cervical adenocarcinoma afforded by cervical cytology screening: a cross-sectional study. ( 24407579 )
2014
44
ERCC1 Expression and Chemosensitivity in Uterine Cervical Adenocarcinoma Cells. ( 24403450 )
2014
45
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Cervical Adenocarcinoma. ( 25341589 )
2014
46
Remission of anti-epiligrin cicatricial pemphigoid after excision of cervical adenocarcinoma. ( 24766621 )
2014
47
Hepatoma-derived growth factor upregulation is correlated with prognostic factors of early-stage cervical adenocarcinoma. ( 25421244 )
2014
48
The prognosis significance of TGF-I^1 and ER protein in cervical adenocarcinoma patients with stage Iba88~a88IIa. ( 25113249 )
2014
49
High Methylation Rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 Genes in Cervical Adenocarcinoma. ( 24407576 )
2014
50
HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. ( 24762548 )
2014

Variations for Cervical Adenocarcinoma

Expression for Cervical Adenocarcinoma

Search GEO for disease gene expression data for Cervical Adenocarcinoma.

Pathways for Cervical Adenocarcinoma

Pathways related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 29)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 CDKN1A CDKN2A ERBB2 ESR1 RASSF1 TP53
2
Show member pathways
12.67 CASP3 ERBB2 ESR1 PTGS2 TP53
3
Show member pathways
12.26 CASP3 CDKN1A CDKN2A TP53
4
Show member pathways
12.25 CASP3 CDKN1A ERBB2 TP53
5 12.18 CASP3 CDKN1A CDKN2A TP53
6 12.07 CASP3 CDKN1A ERBB2 ESR1 TP53
7 12.03 CASP3 CDKN1A PTGS2 TP53
8
Show member pathways
12.01 CASP3 CDKN1A ERBB2 TP53
9 11.98 CASP3 CDKN1A CDKN2A ERBB2 PTGS2 RASSF1
10
Show member pathways
11.92 CDKN1A CDKN2A ERBB2 TP53
11 11.9 CASP3 PTGS2 TP53
12 11.87 CDKN1A PTGS2 TP53
13 11.85 CDKN1A CDKN2A TP53
14 11.83 CDKN1A CDKN2A TP53
15 11.82 CASP3 CDKN1A CDKN2A ERBB2 LAMC2 PTGS2
16 11.79 CDKN1A CDKN2A ERBB2 TP53
17
Show member pathways
11.77 CDKN1A ERBB2 ESR1
18 11.71 LAMC2 PTGS2 TP53
19 11.52 CDKN1A CDKN2A ERBB2 RASSF1 TP53
20 11.51 CASP3 CDKN1A PTGS2
21 11.44 CDKN1A CDKN2A TP53
22 11.42 CASP3 CDKN1A CDKN2A ERBB2 TP53
23 11.4 CDKN1A ESR1 PTGS2
24 11.36 CASP3 CDKN1A TP53
25 11.33 CASP3 CDKN1A PTGS2 TP53
26 11.18 ESR1 PTGS2 TP53
27
Show member pathways
10.92 CDKN1A CDKN2A TP53
28 10.7 CDKN1A TP53
29
Show member pathways
10.51 CDKN1A TP53

GO Terms for Cervical Adenocarcinoma

Cellular components related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.02 CDKN1A CDX2 ESR1 PTGS2 TP53

Biological processes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.93 CASP3 CDKN2A KRT20 TP53 VIL1
2 positive regulation of apoptotic process GO:0043065 9.81 CASP3 CDKN2A PTGS2 TP53
3 negative regulation of cell growth GO:0030308 9.72 CDKN1A CDKN2A TP53
4 response to estradiol GO:0032355 9.65 CASP3 ESR1 PTGS2
5 response to organic substance GO:0010033 9.63 CASP3 CDKN1A PTGS2
6 cell cycle arrest GO:0007050 9.62 CDKN1A CDKN2A RASSF1 TP53
7 response to glucocorticoid GO:0051384 9.61 CASP3 CDKN1A PTGS2
8 negative regulation of B cell proliferation GO:0030889 9.52 CASP3 CDKN2A
9 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.49 CDKN1A TP53
10 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.43 CASP3 CDKN1A CDKN2A
11 negative regulation of immature T cell proliferation in thymus GO:0033088 9.4 CDKN2A ERBB2
12 signal transduction by p53 class mediator GO:0072331 9.37 CDKN1A TP53
13 response to X-ray GO:0010165 9.33 CASP3 CDKN1A TP53
14 Ras protein signal transduction GO:0007265 9.26 CDKN1A CDKN2A RASSF1 TP53
15 replicative senescence GO:0090399 8.8 CDKN1A CDKN2A TP53

Molecular functions related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.8 CASP3 CDKN1A CDKN2A

Sources for Cervical Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....